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Abstract
Glucose-galactose malabsorption (GGM) is due to mutations in the gene coding for the intestinal sodium glucose
cotransporter SGLT1 (SLC5A1). Here we identify the rare variant Gln457Arg (Q457R) in a large pedigree of patients in the
Västerbotten County in Northern Sweden with the clinical phenotype of GGM. The functional effect of the Q457R mutation
was determined in protein expressed in Xenopus laevis oocytes using biophysical and biochemical methods. The mutant
failed to transport the specific SGLT1 sugar analog α-methyl-D-glucopyranoside (αMDG). Q457R SGLT1 was synthesized in
amounts comparable to the wild-type (WT) transporter. SGLT1 charge measurements and freeze-fracture electron
microscopy demonstrated that the mutant protein was inserted into the plasma membrane. Electrophysiological
experiments, both steady-state and presteady-state, demonstrated that the mutant bound sugar with an affinity lower than
the WT transporter. Together with our previous studies on Q457C and Q457E mutants, we established that the positive
charge on Q457R prevented the translocation of sugar from the outward-facing to inward-facing conformation. This is
contrary to other GGM cases where missense mutations caused defects in trafficking SGLT1 to the plasma membrane.
Thirteen GGM patients are now added to the pedigree traced back to the late 17th century. The frequency of the Q457R
variant in Västerbotten County genomes, 0.0067, is higher than in the general Swedish population, 0.0015, and higher than
the general European population, 0.000067. This explains the high number of GGM cases in this region of Sweden.
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Introduction
Next-generation sequencing has rapidly improved the ability to
identify novel monogenic disorders, including congenital diar-
rheas and enteropathies (CODE) in young infants.1,2 Chronic
CODE disorders are generally classified as either secretory diar-
rheas resulting from abnormal electrolyte transport or malab-
sorptive diarrheas caused by failure to absorb nutrients. Malab-
sorption may be generalized, caused by impaired assimilation of
numerous nutrients associated with abnormalities of enteroen-
docrine function or epithelial trafficking and polarity abnormal-
ities.3,4 In contrast, selective malabsorption is caused by abnor-
malities in the digestion or absorption of specific nutrients.
The first CODE disorder described at both a clinical and
molecular level was glucose-galactose malabsorption (GGM),
a potentially lethal defect in intestinal sugar absorption, was
independently reported in 1962.5,6 Subsequently, this clinical
phenotype was identified in 6 cases within a pedigree located
in Northern Sweden.7,8 A simple therapy, removing glucose,
galactose, and lactose (and starch from older infants) from the
diet, effectively treated these patients. We established that GGM
is due to mutations in the gene coding for the intestinal brush
border sodium glucose cotransporter SGLT1 (SLC5A1).9–13 In over
80 GGM patients, most mutations were missense, but nonsense,
frameshift, splice-site, and promoter mutations were identified.
The most common defect of Na+/glucose cotransport amongst
the missense mutations is a failure to insert the transporter into
the plasma membrane.14 We were intrigued about the cause of
GGM in the Västerbotten pedigree traced back to the end of the
17th century (Figure 1).7,8 We were fortunate to obtain a blood
sample from the first case identified on the pedigree, 8 others
diagnosed with the disorder and a few first-degree relatives.
A common Q457R mutation was responsible for the defect in
glucose and galactose transport, and subsequent studies of
Q457C and Q457E mutants showed that the positive charge on
Q457R is responsible. Examining whole-genome sequences of
a control Västerbotten population revealed a higher frequency




We focused on identifying the mutation(s) that caused GGM in
the pedigree first identified by Melin and Meewuisse (1969) in
northern Sweden (Figure 1).7,8 Amongst the 6 patients in this
pedigree, we obtained a blood sample from case 1 for genetic
analysis. Ultimately, we identified an additional 16 GGM cases
referred to the Department of Pediatrics at the University of
Umeå for diagnosis or consultation and blood samples from 9,
including cases 1, 9, 10, 11, 12, 15, 16, and 17. In two cases,
9 and 11, duodenal biopsies were taken as part of their clini-
cal care, but immunohistochemistry on patient 11 was unsuc-
cessful for technical reasons. Patients were born between 1961
and 2004, except case 3, born in 1926 and related to cases 1
and 2. Meeuwisse and Melin (1969) reported on the diagnosis of
patients 1–6.7,8
This research was conducted in accordance with ethical
standards of University of California at Los Angeles, under the
jurisdiction of the Chancellor’s Human Research Committee and
subject to the 1964 Declarations of Helsinki and its later amend-
ments. Written informed consent was obtained from each sub-
ject, or the parents of each minor child, for the collection of a
blood sample and for sharing intestinal biopsies collected for
clinical diagnosis.
The newly diagnosed cases had symptoms in common with
previous ones in that they presented with diarrhea within
days after birth. Glucose was in their stools, and diarrhea
ceased immediately when carbohydrates, apart from fruc-
tose, were removed from their diet. In addition, blood glu-
cose levels remained flat following oral glucose tolerance tests
(2 g/kg). In all cases, the diarrhea was controlled by reduc-
ing the carbohydrate content of their diet, initially by feed-
ing an infant formula with fructose as the only carbohydrate.
The parents of GGM patients were healthy, and those able to
be tested had normal oral glucose tolerance tests. Interviews
amongst relatives and examination of parish registers (available
in the Umea City Library) were used to add new cases on the
pedigree.
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Figure 1. The Northern Swedish Pedigree of GGM patients. The original pedigree, containing cases 1–6, filled symbols (square male, circle female), were traced back to
a couple in the late 17th century.7,8 Four suspected cases were also identified in a family with 12 children (hatched symbol) of a distant relative to case 3. Six additional
GGM patients: 7, 9–12, and 14, have now been placed on this pedigree, but DNA was only obtained for 6 identified cases in all: 1, 9–12, and 3 others not placed in the
pedigree (15–17). The known GGM cases were traced to 4 of the 13 siblings born between 1719 and 1724.
Identification of the Mutation, Site-Directed
Mutagenesis and cRNA Synthesis
Genomic DNA was extracted from the blood sample of patients
1, 9, 10, 11, 12, 15, 16, and 17, and single-stranded conformational
polymorphism (SSCP) screened abnormalities in the SGLT1 gene
in each exon, and mutations identified by Sanger sequencing, as
previously described.9–12 All patients had a mutation in exon 12,
a homozygote mutation of glutamine 457 to arginine. In later
cases, exon 12 of the SGLT1 gene was polymerase chain reac-
tion (PCR) amplified and Sanger sequenced. PCR site-directed
mutagenesis was performed using wild-type (WT) human SGLT1
cDNA as a template.9,10 The sequence of the synthetic oligonu-
cleotide used to produce the Q457R mutation in the sense ori-
entation was 5′-CGATTACATCCGGTCCATCACCAGT-3′, where the
bold letter represents the mutated nucleotide. The mutant plas-
mid was linearized with XbaI, and in vitro transcription was
performed with MEGAscriptTM transcription kit from Ambion by
standard methods.9,12
Uptake and Electrophysiology Experiments on Xenopus
Oocytes
Mature female Xenopus laevis were anesthetized with 0.1% tri-
caine (Sigma-Aldrich, St Louis, MO) buffered with 0.1% NaHCO3
to harvest a portion of the ovary. Stage V-VI oocytes were
selected and maintained at 18◦C in modified Barth’s solution,
supplemented with 50 mg l−1 gentamicin (Sigma), 5.75 mg
l−1 ciprofloxacin (Bayer), and 100 mg l−1 streptomycin sul-
phate/100000 units l−1 penicillin G sodium (Invitrogen, Carlsbad,
CA). One day after isolation, oocytes were injected with 50 ng of
cRNA coding for WT hSGLT1 or mutants and incubated at 18◦C
for 4–7 days. Experiments were performed at 20–22◦C. Nonin-
jected (NI) oocytes from the same donor frog served as controls.
All animal protocols followed guidelines approved by the Univer-
sity of California Chancellor’s Committee on Animal Research
and the ARRIVE (Animal Research: Reporting of In Vivo Experi-
ments) guidelines 2.0.
Oocytes obtained from adult X. laevis were injected with
50 nl (1μg/μl) of cRNA coding for WT or Q457R mutant
human SGLT1.15–17 After 3 days, 50μM 14C-α-methyl-D-glucoside
(αMDG) uptake was measured.17,18
SGLT1 membrane currents were measured in the oocytes
expressing either WT or mutant Q457R proteins, using a 2-
electrode voltage clamp method.17,19,20 The steady-state sugar-
dependent currents were obtained for each membrane volt-
age as the difference between the current measured at steady
state in the presence and absence of sugar in 100 mM Na+. At
each voltage, the currents recorded at different sugar concen-
trations were used to obtain the transporter’s apparent affin-
ity (K0.5) for the sugar.21 The transient SGLT1 charge move-
ments (Q), with each 100 ms voltage pulse from the hold-
ing potential of −50 mV to each test membrane potential Vm
between +50 and −150 mV, were calculated by integrating the
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presteady-state current (current obtained at 100 mM Na+ in the
absence of sugar). The data were fitted to the Boltzmann equa-
tion: (Q-Qqhy)/Qmax = 1/[1 + exp(Vm-V0.5)zF/RT], where maxi-
mal charge Qmax = Qdep—Qhyp (Qdep and Qhyp are the charges at
depolarizing and hyperpolarizing limits), F is the Faraday con-
stant, R is the gas constant, T is absolute temperature, V0.5 is
midpoint voltage, and z is the apparent valence of the voltage
sensor.20,21 The time constant (τ ) of the SGLT1 transient cur-
rents (or presteady-state currents) at each membrane potential
was estimated for the ON-currents when membrane potential
was stepped to the test potential from the holding potential
(−50 mV). The transient ON currents were fitted to a single expo-
nential equation: I = Io exp(-t/τ ), where I is the transient cur-
rent (total current after subtraction of the oocyte capacitive and
steady-state current), Io is the maximum current at the begin-
ning of the pulse, and t is time after the onset of the voltage-
step.19,20,22 All the experiments were performed at 22◦C.
Western Blot Analysis
The WT and Q457R mutant SGLT1 proteins were extracted from
cRNA-injected oocytes as previously described.11,12,23 The vol-
ume equivalent of 1/3 of oocyte was run on a 12% sodium
dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
mini-gel and electro-transferred to nitrocellulose membrane.
As controls, NI oocytes extracts and rabbit brush border mem-
brane vesicles samples were loaded in the same gel. SGLT1 was
detected using an anti-peptide polyclonal antibody raised to
residues 602–613 in the C-terminal portion of rabbit SGLT1 at a
dilution of 1:1000.12
Freeze-fracture and Immunohistochemistry
Oocytes expressing WT or Q457R mutant SGLT1 and NI oocytes
were fixed and freeze-fractured as previously described.11,24,25
Small intestinal biopsies from GGM patient 9 (Figure 1) and
a standard control subject were fixed for 2 hr in Carnoy’s solu-
tion (60% absolute alcohol, 30% chloroform, 10% acetic acid)
and embedded, sectioned, and immune-probed as previously
described.23 Incubation with the primary antibody was per-
formed overnight in an anti-peptide antibody raised to residues
564–575 of the rabbit SGLT1 amino acid sequence at 1:100
dilution.26 After washing with phosphate-buffered saline (PBS)
3 × 10 min, sections were covered with 10 μg/ml rhodamine-
labeled affinity-purified goat anti-rabbit IgG (Jackson Immuno
Research Laboratories, Inc.) for 40 min and then washed with
PBS 3 × 10 min. Nuclei were further stained with 2mg/ml
DAPI (4’,6-Diamidino-2-phenylindole dihydrochroride, Research
Organics Inc)-for 40 min. As controls, normal tissue sections
were incubated with normal rabbit serum and labeled secondary
antibody, or incubated with PBS but not with primary antibody
before staining with the secondary antibody.
Results
Molecular analysis of the SGLT1 (SLC5A1) gene in 9 GGM patients
(1, 9, 10, 11, 12, 15, 16, and 17) revealed a variant exon 12 by
SSCP, and sequencing of the exon in both alleles showed a CAG
to CGG mutation at nucleotide 1380 resulting in a Q457R muta-
tion (Figure 2). Where genomic samples were available, parents
of cases 9, 15, 16, and 17 were heterozygotes, and unaffected sib-
lings of cases 12, 16, and 17 were either heterozygotes (12, 16)
or normal (17). This confirms the autosomal recessive mode of
inheritance previously noted.7,8,27
Figure 2. Sanger sequencing of child with GGM and his parents. The proband has
a CGG-R457 mutation, while the mother and father are heterozygotes.
Figure 3. αMDG uptake by WT and Q457R mutant SGLT1. Oocytes were injected
with 50 nl (1 μg/μl) of cRNA coding for WT or Q457R mutant SGLT1. After 3
days, uptake of 50 μM 14C-αMDG was measured. Values represent the mean of
8 oocytes and the error bars indicate the standard error. Q457R mutant uptake
was not different from uptake by NI oocytes, 1.7% of the WT uptake (3 vs. 180
pmoles/h/oocyte).
To investigate if the Q457R mutant was functional, we mea-
sured the uptake of 50 μM 14C-αMDG by oocytes injected with
WT and Q457R SGLT1 cRNA (Figure 3). Uptake by the mutant
protein was 1.7% of WT uptake (180 pmoles/h/oocyte) and not
different from NI oocytes (3.1 ± 0.1 and 3.4 ± 0.1 pmol/h/oocyte,
respectively). These results indicate either that the mutant pro-
tein was not synthesized or that it was not trafficked correctly
between the endoplasmic reticulum and the plasma membrane
or functionally defective. To distinguish between these alterna-
tives, we determined the expression of the mutant protein in
oocytes using western blotting and the density of Q457R SGLT1
in the oocyte plasma membrane using freeze-fracture electron
microscopy, and functional properties of Q457R using electro-
physiology. Na+/glucose cotransport generates an inward Na+
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Figure 4. Western blot analysis of WT and Q457R mutant SGLT1 expressed
in oocytes. Seven days after injection with WT or Q457R mutant cRNA, pro-
tein was extracted from 2 oocytes each. The equivalent to 1/3 oocyte was run
in a 12% SDS-PAGE gel and after transfer to a nitrocellulose membrane, and
was probed with an SGLT1 antipeptide antibody raised to residues 602–613, at
1:1000 dilution. Both WT and Q457R mutant proteins ran as 2 broad bands, one
70 kDa band which corresponds to the complex glycosylated form, less intense
in the mutant, and another of ∼60 kDa which corresponds to core glycosylated
form.11,23
Figure 5. (Freeze-fracture) P fracture face of the plasma membrane of a NI oocyte
and oocytes injected with Q457R or WT cRNA. NI oocyte (A) showed 7-nm-
diameter particles in the P-face at a density of 200/mm2, whereas in WT injected
oocyte (B), the density of particles increased to 1000/mm2. Similar density was
obtained in Q457R cRNA injected oocytes (C). Q457R injected oocyte is the same
as the one in Figures 7B and 8A. The 25 mM Na+/glucose current was −800 nA
at –50 mV for the WT oocyte and 0 for Q457R (Figure 7); the SGLT1 charge move-
ments were 8.5 and 3.7 nC (Figure 8A). Scale bar 200 nanometers.
current directly proportional to glucose transport, and SGLT1 in
the plasma membrane exhibits charge movements Q that are
directly proportional to the density of the protein in the mem-
brane.14 Western blotting shows that the mutant protein was
synthesized and glycosylated, as was the WT protein (Figure 4).
The complex and core glycosylated Q457R protein pattern at 70
and 60 kD was similar for WT and mutant protein, even though
the level of complex glycosylation was lighter for the mutant
than WT. We have previously shown that N-linked glycosylation
is not required for the functional expression of SGLT1.27 Freeze-
fracture electron microscopy revealed that SGLT1 was inserted
into the P-face of the plasma membrane of oocytes, and the
density of the 7 Å particles was directly proportional to SGLT1
functional expression.24,25 Figure 5 shows representative freeze-
fracture images of NI oocytes and oocytes injected with WT
and Q457R SGLT1 cRNA. All oocytes were processed in parallel
from the same donor frog after measuring SGLT1 steady-state
and pre-steady-state currents (see below). The density of the
SGLT1 particles in the P-face of the control oocyte was 200/μm2,
and this increased to 1000/μm2 for the oocyte injected with WT
SGLT1 cRNA, and 600/μm2 for Q457R SGLT1. These results for
control oocytes and those injected with human WT SGLT1 cRNA
agreed with previous results.12,25 The density of Q457R in the
Figure 6. Immunolocalization of SGLT1 protein in human small intestine of a
normal (control) (A) and a GGM patient (9) with the Q457R missense mutation
(B). Double staining procedures shows SGLT1 (red) as a sharp line localized to
the brush border of the enterocytes and the basal nucleus stained in blue. Goblet
cells between the enterocytes were unstained for SGLT1. There were no differ-
ences in location of SGLT1 in enterocytes from the normal and the GGM (magni-
fication x125). In a separate case of GGM, C292Y, the mutant protein did not reach
the brush border membrane and was trapped just above the nuclei.14 Scale bar
30 micrometers.
plasma membrane was lower than for WT, and this is consis-
tent with the lower level of functional expression of the mutant
protein (on average, Qmax 3.7 nC for Q457R vs. 8.8 nC for WT, see
below). These results suggest that the defect in αMDG uptake
(Figure 3) is not due to defective mutant Q457C SGLT1 synthesis
or trafficking from the ER (endoplasmic reticulum) to the plasma
membrane but to an incompetent transporter.
Does the expression of mutant SGLT1 in the oocyte reflect
the expression in the patient’s enterocytes? Small bowel biop-
sies from GGM patient 9 was examined by immunohistochem-
istry (Figure 6). The mutant protein was detected as a thin red
line over the brush border membrane of enterocytes, just as
in a biopsy from a control subject. No immunofluorescence of
SGLT1 protein was detected in control sections incubated with
control rabbit serum. However, given the low resolution of light
microscopy, the immunofluorescence does not actually show
that the mutant SGLTs are inserted into the plasma membrane
of the enterocyte brush border in the GGM patient, but only close
to it.
Electrophysiological studies provided insight into the func-
tional defects of Q457R SGLT1 in the plasma membrane. Figure 7
shows examples of the steady-state currents recorded in oocytes
expressing the WT and Q457R proteins. The currents elicited
by 25 mM αMDG and 0.1 mM phlorizin for WT SGLT1 depend
on voltage: inward Na+ current increased in a sigmoid fashion
from 0 nA at +50 mV to 1500 nA at −150 mV (Figure 7A). This
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Figure 7. Steady-state currents induced by αMDG and phlorizin in WT and Q457R mutant proteins. Seven days after injection with cRNA, oocytes expressing WT
and mutant SGLT1 were perfused with 100 mM NaCl buffer and currents were measured using a 2-electrode voltage clamp. The difference in steady-state currents
measured in the absence and in the presence of αMDG or phlorizin (Pz) is plotted at each test potential from −150 to +50 mV. A. In WT, 25 mM αMDG induced Na+
inward current (1500 nA at −150 mV) whereas 0.1 mM Pz blocked the Na+ leak current (+143 nA at −150 mV). B. In Q457R mutant, both 100 mM αMDG and 0.5 mM
Pz inhibited the Na+ leak current (+180 and + 360 nA at −150 mV, respectively). Similar results were obtained on oocytes from 3 different frog donors. The oocyte
expressing Q457R-cRNA is the same one as shown in the oocyte in Figure 8B (Q/V with and without sugar) and Figure 5 (freeze-fracture).
current required the presence of external Na+ and was reversibly
blocked by the addition of 0.1 mM phlorizin, the specific, non-
transported competitive inhibitor (not shown). The Na+/glucose
current is directly proportional to the rate of glucose transport,
with a coupling of 2 Na+ and 1 glucose.14 The addition of 0.1 mM
phlorizin in the absence of external glucose (closed circles) pro-
duced a small outward current that reached a value of 143 nA at
−150 mV. This so-called SGLT1 leak current was not observed in
NI oocytes.
In contrast, no inward sugar-stimulated Na+ currents were
observed for the mutant even when the external αMDG con-
centration was raised to 100 mM, but instead, αMDG inhibited
the Na+-leak current (Figure 7B). This leak current was blocked
by 0.5 mM phlorizin and amounted to 360 nA at −150 mV.
αMDG reduced the Q457R leak current in a concentration-
dependent manner, with an apparent inhibitory constant Ki of
52 ± 4 mM, 2 orders of magnitude higher than the apparent Km
for Na+/glucose cotransport (0.34 ± 0.02 mM). The Ki for phlo-
rizin, based on the concentration needed to inhibit the Q457R
leak, was an order of magnitude higher than that for the WT
leak. These results suggest that αMDG and phlorizin bind to
Q457R, albeit at low affinities.
In the presence of Na+ and absence of sugar, SGLT1 exhibits
presteady-state currents after step changes in membrane poten-
tial. These reflect the conformational changes of the transporter
in the membrane (charge movement, Q). Voltage-jump experi-
ments showed that the mutant exhibited presteady-state cur-
rents characteristic of WT, indicating that it was in the plasma
membrane. Figure 8 shows the charge/voltage relationship Q/V
for WT and Q457R mutant transporters. The data were fitted to
a Boltzmann relation, and the curves were similar except that
Qmax for Q457R was only 60% on average of that for WT, 3.7 ± 0.2
nC vs. 8.8 ± 0.3 nC. Qmax is related to the number N of SGLTs
in the plasma membrane: N = Qmax/ze, where z is the apparent
valence of the moveable charge (the limiting slope of the Q/V
curve), and e is the elementary charge.11,12,20,23,24 There were no
differences in the apparent valence (z) or the V0.5 (membrane
potential for 50% maximal charge), which were 1.4 ± 0.1 and
−46 ± 4 mV for the mutant, and 1.4 ± 0.1 and −50 ± 6 mV for
WT. The 40% reduction in Qmax for the mutant relative to the
WT agrees with the freeze-fracture electron micrographs shown
in Figure 5.
In WT, the addition of external sugar blocked the presteady-
state currents.14,21,22 Sugar reduced Qmax and shifted V0.5 to pos-
itive values with K0.5 values of 1 mM. Phlorizin also blocked Qmax
with a Ki of 0.1 uM but with no shift in V0.5. In contrast, sugar did
not abolish the presteady-state currents of Q457R but instead
increased Qmax with a positive shift in V0.5 (Figure 8B). Qmax, at
50 mM αMDG, was 15.5 nC relative to 11.5 nC in the absence
of sugar. In this experiment, V0.5 shifted from −27 mV in the
absence of sugar to +7 mV in the presence of 50 mM αMDG.
There was no change in z (1.1). These sugar-induced changes
in capacitive current were accompanied by a shift in the volt-
age dependence of the relaxation time constants. The time con-
stant was independent of voltage between +50 and −100 mV
at 4 ms but increased steeply between −100 and −150 mV to
40 ms, while the time constant for WT SGLT1 increased steadily
between +50 and −150 mV from 4 to 28 ms.
Discussion
In 1969, Meeuwisse and Melin identified 6 GGM patients in
Northern Sweden, and another 4 suspected cases, who are
pedigree members traced back to the 17th century.7,8 We have
extended this discovery with an additional 11 GGM cases and
placed 6 on the pedigree (Figure 1). In addition, we have iden-
tified the mutation in the SGLT1 (SLC5A1) gene responsible for
the malabsorption syndrome, Q457R, in 8 cases (6, 9–12, 15–
17). This variant is relatively frequent, 0.0067, in the genome of
300 Västerbotten residents over 80 years of age in the ACpop
genomic database.28 This frequency is 4.5-times higher than a
cross-section of the Swedish population, 0.0015, in the SweGen
genomic database,29 and an order of magnitude higher than
both the European (non-Finnish) and Finish genomes, 0.00011
and 0.00014, and 0.000067 in the GnomAD databases.30 The high
frequency of the Q457R in Västerbotten genomes and the pedi-
gree dating back to the 17th century (Figure 1) is probably due
to a founder effect, combined with the historic low population
density and large distances between towns and villages.
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Figure 8. A. Charge-voltage (Q/V) relationships for WT and Q457R SGLT1. A. Charge was obtained by integration of SGLT1 current transients in the absence of sugar
(see methods). The symbols correspond to the experimental data after the subtraction of the NI oocyte values, and normalized to WT charge at + 50 mV. The dotted
lines are drawn according to the Boltzmann relation. Mutant Qmax (maximal charge transfer) was 40% of the WT value (3.7 ± 0.2 vs. 8.8 ± 0.3 nC). The V0.5 values were
−47 and −50 mV, and z 1.4. B. Q/V relationships of Q457R SGLT1 in the absence and in the presence of the 50 mM αMDG. Q was obtained by the integration of current
transients in the absence and in the presence of 50 mM αMDG. The symbols correspond to the experimental data and the curves are drawn according to the Boltzmann
relation. The addition of 50 mM αMDG induced an increase of Qmax, from 11.5 to 15.5 nC, and a shift of V0.5 from −27 to + 7 mV, but no change in z (1.1).
The Q457R mutant expressed in oocytes is defective in
Na+/glucose cotransport, as judged by the lack of αMDG-uptakes
and absence of glucose-stimulated Na+ inward currents (Figures
3 and 7B). This defect is not due to the common trafficking defect
as in other GGM mutants where the protein is trapped between
the endoplasmic reticulum and the plasma membrane (D28N,
L149R, C292Y, A304V, G318R, C355S, A468V, and R499H),9,12,13
but instead a defect in glucose transport across the plasma
membrane. As evident from freeze-fracture electron microscopy
(Figure 5), and current and charge movements (Figures 7 and 8A),
Q457R is inserted into the plasma membrane and retains partial
function. Namely, αMDG blocks the Q457R Na+-leak and binds
to the transporter, shifting the Q/V curves (Figure 8B). Likely,
the defective Q457R SGLT1 is also inserted into the brush border
membrane of enterocytes in patients (Figure 6), unlike the C292Y
GGM mutant that is trapped between the nuclei and brush bor-
der membrane.14
Changes in SGLT1 Kinetic Model for WT and Mutant
Q457R
The steady-state and presteady-state kinetics of WT SGLT1
has been described by a nonrapid-equilibrium, ordered, 6-state
model.19 The protein alternatively faces the external and inter-
nal membrane surfaces (Figure 9). Two external Na+ ions bind to
the empty transporter C1 to form C2 before glucose. After sugar
binding, the fully-loaded transporter (C3) undergoes an isomer-
ization, resulting in the substrate-binding sites facing the cyto-
plasm (C4), where glucose is released (C5) before Na+ (C6). The
model includes a Na+ leak (C2 ↔ C5) in the absence of glucose.
In WT SGLT1, the steady state distribution of the 6-states in the
absence of sugar and the presence of 100 mM Na+ is 95% in C2 at
−150 mV and 100% in C6 at +50 mV. Rapid jumps in membrane
voltage between −150 and +50 mV produce transient charge
movements (Q) with a V0.5 of −50 mV. The addition of external
glucose redistributes the WT state distribution to 70% in C5 and
25% in C3 at −150 mV and 100% in C6 at +50 mV. This eliminated
charge transfer for voltage jumps between −150 and +50 mV.
Figure 9. Six-state kinetic model of Na+/glucose uptake by SGLT1 expressed in
oocytes. The external Na+ concentration was 100 m-equiv/l and external glu-
cose concentration was 0–100 mM. As indicated in light blue the internal Na+
was 5 m-equiv/l and the cytoplasm was sugar-free. For simulations, the rate con-
stants are: WT hSGLT1: k12 = 14000 M –2s–1, k21 = 300 s–1, k16 = 600 s–1, k61 = 25
s–1, k23 = 45000 M –1s–1, k32 = 20 s–1, k34 = 50 s–1, k43 = 50 s–1, k45 = 800 s–1,
k54 = 7800 M–1s–1, k65 = 4500 M–2s–1, k56 = 10 s–1, and k25 = 0.3 s–1. k54 = 7800
M–1s–1 and k52 = 0.001 s–1 were determined by microscopic reversibility.15 The
rate constants of mutant Q457R that accounted for its kinetics were the same as
WT, except for k23 = 800 M–2s–1, k25 = 50 s–1, k34 = 0 s–1, and k43 = 0 s–1. Again,
k54 = 140 M–1s–1 and k52 = 0.2 s–1 were determined by microscopic reversibility.
u = FV/RT, α’ = 0.3, δ = 0.7. α” = 0.
For mutant Q457R, translocation of sugar across the mem-
brane from state 3 to state 4 is blocked (k34 = k43 = 0). The lower
affinity for sugar and phlorizin binding to C2Na2 is accounted for
by reducing the ratios k23/k32 and k27/k72. In the absence of exter-
nal glucose, there is an increase in Na+-leak due to increases in
the rate-constants (k25, k52) for the transition between C2 and
C5. Subsequently, the state distribution at −150 mV changes to
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Figure 10. Molecular model showing sugar-binding site of WT hSGLT1 and mutant Q457R. The molecular models of the outward and inward-facing conformations
of hSGLT1 were based on the crystal structures of the sodium sialic acid symporter SiaT from Proteus mirabilis (PDB ID 5NV9) and the sodium glucose cotransporter
vSGLT from Vibrio parahaemolyticus (PDB ID 3DH4).34 Computational and experimental approaches were used to validate the homology models. A sugar-binding site
in outward open conformation. The sugar coordinating residues Q457, H83, Y290, N78, and E102 are not shown. Note that Q457R does not interact with sugar in this
conformation. B. The sugar-binding site in the inward conformation. Note that the inward tilt of TM10 positions Q457 to interact with the pyranose oxygen and the
C#6 –OH of glucose. C. Sugar binding site for mutant Q457R in the inward conformation. Note that in this conformation the side-chain of Arg457 encounters steric
hindrance to binding with glucose.
45% C2 and 50% C5 at −150 mV, and 100% in C6 at +50 mV.
The increase in Na+ leak (k25) reduces the charge transfer by
∼20% when membrane voltage is rapidly jumped from −150
to + 50 mV. On addition of external glucose, occupancy in C3
is increased to 90% at the expense of C5 at −150 mV and 100%
in C6 at +50 mV. Thus, when voltage is jumped between −150
and +50 mV, there is a shift of V0.5 to positive values and an
increase in Qmax (Figure 8B).
Molecular Basis for Q457R Transport Defect
What is the molecular basis for the Q457R transport defect?
Clues emerge from functional studies of other Q457 mutants
expressed in oocytes: First, the Q457C-mutant, unlike Q457R,
transports αMDG with a K0.5 of 13 mM compared to 0.5 mM
for WT, and a Na+/glucose coupling coefficient of 6 vs. 2 for
WT.31 The latter reflects a large Na+-leak through Q457C. Phlo-
rizin blocked transport with a Ki 30-fold higher than WT; sec-
ond, chemical alkylation of Q457C with MTSEA+ (2-aminoethyl
methanethiosulfonate hydrobromide), MTSHE0 (2-hydroxyethyl
methanethiosulfonate), and TMR6M (tetramethylrhodamine-6-
maleimide), but not MeMTS0 (methyl methanethiosulfonate) or
iodoacetamide, blocks transport but not sugar binding32–34; and
third, Q457E supports Na+/glucose cotransport with an αMDG
K0.5 of 2.8 mM.33 These data suggest that the positively-charged
and bulky arginine at position 457 blocks the translocation of
glucose bound from the outward-facing conformation to the
inward-facing conformation. Finally, inspection of structural
models of human SGLT1 indicates that glucose is not bonded
with Q457 on the outer end of helix 10 in the outward-open
conformation but is in the inward-facing conformation with H-
bonding to the pyranose oxygen and the C6 hydroxyl group.34,35
This is facilitated by the inward movement of the outer ends of
transmembrane helix 10 (TM10) toward the glucose binding site,
bringing Q457 within range for H-bonding.14,34 However, due to
the bulky arginine, there is an obstruction to the inward move-
ment of Q457R on helix 10 towards the sugar-binding site (Figure
10). We propose the bulky positively-charged arginine at position
457 prohibits the inward tilt of TM10, thereby blocking glucose
translocation.
Summary
We have increased the number of GGM cases assigned to an
extensive pedigree in Västerbotten County, Sweden, traced to
the late 17th century to 21, and identified the mutation Q457R in
Lostao et al. 9
the SGLT1 (SLC5A1) gene responsible for malabsorption. In a het-
erologous expression system, X. laevis oocytes, we have found
that the mutant protein is inserted into the plasma. In a duo-
denal biopsy from a GGM patient the mutant protein is in the
brush border membrane of enterocytes. Among GGM patients,
the insertion of Q457R protein into the plasma membrane is
unique as other mutations result in trafficking defects between
the ER and the membrane. The defect in glucose transport by
Q457R is due to a failure in the translocation of bound glu-
cose across the membrane. This is likely caused by the positive
charge on the bulky arginine side chain restricting a key con-
formation change in the outer end of transmembrane helix 10,
preventing occlusion of the glucose binding site. In conclusion,
studies of this isolated pedigree of GGM patients confirm the
autosomal recessive mode of inheritance and provides unique
insight into the molecular mechanism of glucose transport by
SGLT1.
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